IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#807
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$685.8B
David A. Ricks
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Headcount
39.0K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = LLY ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$LLY ELI LILLY & Co | 59 | 74 | 61 | 59 | 63.6x | 50.0x | 56.4% | 13.3% | 82.7% | 31.4% | 24.6% | 55.7% | 0.8% | 324.0x | $685.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ELI LILLY & Co (LLY) receives a "Hold" rating with a composite score of 58.8/100. It ranks #807 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
David A. Ricks
Chief Executive Officer
Labor Force
39,000
74
24
72
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for LLY
HQ Base
Indianapolis, Indiana
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for LLY.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 74 | 82 | -8DRAG |
| MOMENTUM | 59 | 53 | +6ALPHA |
| VALUATION | 61 | 44 | +17ALPHA |
| INVESTMENT | 24 | 10 | +14ALPHA |
| STABILITY | 72 | 69 | +3NEUTRAL |
| SHORT INT | 70 | 81 | -11DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 63.1% vs WACC 9.5% (spread +53.6%)
GM 83% vs sector 43%, OM 31% vs sector 1%
Capital turnover 1.99x
Rev growth 56%, 10yr history
Interest coverage N/A, Net debt/EBITDA 1.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns ELI LILLY & Co a Hold rating, with a composite score of 58.8/100 and 3 out of 5 stars. Ranked #807 of 7,333 stocks, LLY presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
LLY earns a quality score of 74/100, indicating above-average business quality. The company reports a return on equity of 56.4% (sector avg: -2.5%), gross margins of 82.7% (sector avg: 42.5%), net margins of 24.6% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
LLY's value score of 61/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 63.61x, an EV/EBITDA of 49.98x, a P/B ratio of 35.89x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
ELI LILLY & Co's investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 55.7% vs. a sector average of 5.9% and a return on assets of 13.3% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
LLY demonstrates moderate momentum with a score of 59/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 55.7% year-over-year, while a beta of 0.66 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
LLY shows good financial stability with a score of 72/100. Key stability metrics include a beta of 0.66 and a debt-to-equity ratio of 324.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
LLY carries a short interest score of 70/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 324.00x). At $685.8B market cap (mega-cap), ELI LILLY & Co offers reasonable institutional liquidity.
LLY offers a modest dividend yield of 0.8%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
ELI LILLY & Co is a mega-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #807 of 7,333 overall (89th percentile). Key comparisons include ROE of 56.4% exceeding the -2.5% sector median and operating margins of 31.4% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While LLY currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Quality (74) vs Investment (24) — closing this gap could shift the rating.
EV/EBITDA 336% ABOVE SECTOR MEDIAN
ROE 2375% BELOW SECTOR MEDIAN
Gross Margin 95% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ELI LILLY & Co (LLY) as a Hold with a composite score of 58.8/100 at a current price of $1045.49. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in quality (74th percentile) and stability (72th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (24th percentile) and momentum (59th percentile) tempers our overall conviction. We assign a Narrow Moat rating (63/100), Medium uncertainty, and Standard capital allocation.
Key items to watch: balance sheet deleveraging progress; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ELI LILLY & Co holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 58.8/100 places it at rank #807 in our full 7,333-stock universe. As a mega-cap company with a $685.8B market capitalization, ELI LILLY & Co benefits from significant scale, distribution networks, and brand recognition that smaller competitors cannot easily replicate.
Revenue is growing at 56%, though momentum at the 59th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 83% (+40.2pp vs sector) narrow to operating margins of 31% (+30.1pp vs sector) and net margins of 24.6%, yielding a gross-to-net conversion rate of 30%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $1045.49, ELI LILLY & Co is trading near fair value based on current fundamentals. Our value factor score of 61/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 63.6x (a 186% premium to the sector median of 22.3x), EV/EBITDA of 50.0x (at a premium), P/B of 35.9x, P/S of 16.6x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
Gross margins of 83% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 56.4% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 56% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Return on assets of 13.3% indicates efficient deployment of the full asset base, not just equity capital.
A P/E of 63.6x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
We assign a Medium uncertainty rating to ELI LILLY & Co. The stock presents a balanced risk profile: significant leverage (324% debt-to-equity) and low beta of 0.66 — while defensive, this may indicate limited upside participation in bull markets. While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: significant leverage (324% debt-to-equity); low beta of 0.66 — while defensive, this may indicate limited upside participation in bull markets; elevated valuation multiple (P/E 63.6x) that leaves limited margin for error. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 72th percentile and quality factor at the 74th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 83% provide a buffer against cost pressures; above-average stability (72th percentile) suggests predictable business dynamics; large-cap scale ($685.8B) provides resilience. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate ELI LILLY & Co's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 56.4%, and the balance sheet is managed within acceptable parameters (D/E: 324%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; ELI LILLY & Co falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. The 0.76% dividend yield provides some income return, but the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, ELI LILLY & Co receives a Hold rating with a composite score of 58.8/100 (rank #807 of 7,333). Our quantitative framework assigns a Narrow Moat (63/100, trend: stable), Medium uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 58/100.
Our analysis supports a neutral stance on ELI LILLY & Co. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign ELI LILLY & Co a Narrow Moat rating with a composite moat score of 63/100. The ROIC-WACC spread of +53.6% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that ELI LILLY & Co can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 19.6/20.
The strongest moat sources are margin superiority (19.6/20) and economic value creation (16.6/20). GM 83% vs sector 43%, OM 31% vs sector 1%. ROIC 63.1% vs WACC 9.5% (spread +53.6%). These pillars form the core of ELI LILLY & Co's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (3.6/20) and financial resilience (8.6/20). Capital turnover 1.99x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ELI LILLY & Co's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 83% providing a solid profitability foundation, operating margins of 31% reflecting effective cost management, robust top-line growth of 56% expanding the revenue base. The margin cascade from 83% gross to 31% operating to 24.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 74th percentile.
The margin profile shows gross margins of 83%, operating margins of 31%, net margins of 24.6%. Return metrics include ROE of 56.4% and ROA of 13.3%. Relative to the Manufacturing sector, gross margins are 40.2 percentage points above the sector median of 43%, and ROE of 56.4% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 324%, which may limit financial flexibility, a dividend yield of 0.76%, revenue growth of 56%. The sector median D/E is 0%, putting ELI LILLY & Co at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Elevated leverage (324% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Above 50MA
37.18%
Net New Highs
+51081

The $685.8B question: What happens when a company this good becomes this expensive? In the alphabet soup of healthcare investing, few stories capture the tension between innovation and regulation quite like ELI LILLY & Co. The company stands at the intersection of scientific possibility and market reality. At $685.8B in market capitalization, ELI LILLY & Co (LLY) currently ranks #165 in our quantitative model, with a composite score of 77.0/100. That places it firmly in "Strong Buy" terr
Company gains exclusive mainland China rights to ecnoglutide, approved for diabetes and under obesity review.

Viking Therapeutics' weight-loss drug candidate VK2735 has posted strong mid-stage data and is in phase 3 clinical trials, positioning it as a potential disruptor in the rapidly growing obesity drug market. While the stock could deliver outstanding returns if it successfully navigates clinical and regulatory hurdles, investors should be aware of significant risks including potential clinical setbacks and increased market competition.

Eli Lilly is positioned as a resilient investment that can withstand market downturns due to its dominant position in diabetes and weight-loss drug markets. The company's blockbuster drug Zepbound (tirzepatide) became the world's best-selling drug, and its pipeline includes promising candidates like orforglipron and retatrutide. With diversified operations across oncology, immunology, and neuroscience, plus AI initiatives in drug development, Eli Lilly is expected to maintain strong financial performance and dividend growth even during economic challenges.

Novo Nordisk stock has fallen 67% from its 2024 peak to around $47/share, but the author sees this as a buying opportunity similar to five years ago when the GLP-1 craze began. The company has regained market leadership with FDA-approved oral versions of Wegovy and Ozempic, though Eli Lilly is expected to launch competing pills in Q2 2026. Trading at a below-market price-to-free-cash-flow ratio of less than 23 with 17.5% projected FCF growth and a 3.8% dividend yield, the author recommends buying and holding the stock long-term.